Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment.

We should be able to add anti-CTLA-4 or anti-LAG3 and have double or triple the response rate." Monoclonal antibodies ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference in Chicago, highlighting the safety and efficacy of its product, ADG126, an anti-CTLA-4 masking antibody, in combination ...

Its lead clinical candidate is gotistobart (BNT316/ONC-392), a next generation anti-CTLA-4 antibody that allows CTLA-4 to recycle and maintain its protective function against autoimmune diseases while ...

Anti-CTLA-4 antibodies: version 2.0 The approval in 2011 by the US Food and Drug Administration of the first cytotoxic T lymphocyte protein 4 (CTLA-4) antagonistic antibody, Bristol-Myers Squibb ...

Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior platinum-based chemotherapy,” said ...

Additionally, siRNA ablation of DC CTLA-4 leads to increased efficacy of a DC vaccine to mount an anti-tumor response in various cancer models, suggesting that DC CTLA-4 modulation could be a rational ...

SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...